Association between leukotriene-modifying agents and suicide: what is the evidence?

Abstract:

:The US FDA has issued safety alerts and required manufacturers of leukotriene-modifying agents (LTMAs), including montelukast, zafirlukast and zileuton, to include suicide and neuropsychiatric events as a precaution in the drug label. This paper reviews the existing evidence on the potential association between the LTMAs and suicidal behaviour. We conducted a literature search of MEDLINE, EMBASE and International Pharmaceutical Abstracts from 1995 to 2010 (inclusive) to identify pertinent studies and reports. We also examined data obtained from the FDA adverse event reporting system. To date, there are no well conducted, comparative, observational studies of this association, and the safety alerts are based primarily on case reports. While the FDA safety alerts apply to all three LTMAs, montelukast (known by its trade name Singulair®) is by far the most widely used of these drugs and most of the reports to date regarding suicide pertain to montelukast. From 1998 to 2009 there were 838 suicide-related adverse events associated with leukotrienes reported to the FDA, of which all but five involved montelukast. Nearly all cases were reported in 2008 and 2009 (96.1%) after the FDA warnings. LTMAs are approved for use in asthma and allergic rhinitis, and are effective drugs. Both of these diseases are also associated with suicide, making confirmation of the association more difficult. Given the lack of good evidence, we recommend that a large observational cohort or case-control study be conducted to quantify the association between LTMAs and suicide. Until then, when prescribing LTMAs, clinicians should consider the potential for suicide and monitor patients who may be at elevated risk carefully for suicidal ideation or psychiatric symptoms associated with suicidal behaviour.

journal_name

Drug Saf

journal_title

Drug safety

authors

Schumock GT,Lee TA,Joo MJ,Valuck RJ,Stayner LT,Gibbons RD

doi

10.2165/11587260-000000000-00000

subject

Has Abstract

pub_date

2011-07-01 00:00:00

pages

533-44

issue

7

eissn

0114-5916

issn

1179-1942

pii

1

journal_volume

34

pub_type

杂志文章,评审
  • Quantitative Risk-Benefit Analysis of Probiotic Use for Irritable Bowel Syndrome and Inflammatory Bowel Disease.

    abstract::Probiotics have seen widespread use for a variety of gastrointestinal problems, especially in two common disorders: irritable bowel syndrome and inflammatory bowel disease. Since a wide variety of probiotic preparations has been used, and despite a large number of studies performed, a great deal of heterogeneity exist...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.1007/s40264-015-0349-x

    authors: Bennett WE Jr

    更新日期:2016-04-01 00:00:00

  • Reversal Strategies for NOACs: State of Development, Possible Clinical Applications and Future Perspectives.

    abstract::The non-vitamin K antagonist oral anticoagulants (NOACs) are used for thromboembolic prophylaxis of patients with atrial fibrillation and in the treatment as well as secondary prophylaxis of patients with venous thromboembolism. Even though NOACs have a better safety profile than vitamin K antagonists (VKAs), there wi...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.1007/s40264-015-0357-x

    authors: Husted S,Verheugt FW,Comuth WJ

    更新日期:2016-01-01 00:00:00

  • Liver damage associated with minocycline use in acne: a systematic review of the published literature and pharmacovigilance data.

    abstract:OBJECTIVE:Minocycline is an antibacterial drug used in the treatment of acne. Concern has been expressed over the possibility of severe adverse reactions to minocycline, including hepatitis. This study set out to identify and characterise reported cases of hepatotoxicity associated with the use of minocycline. METHODS...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.2165/00002018-200023040-00006

    authors: Lawrenson RA,Seaman HE,Sundström A,Williams TJ,Farmer RD

    更新日期:2000-10-01 00:00:00

  • Fatal venous thromboembolism associated with different combined oral contraceptives: a study of incidences and potential biases in spontaneous reporting.

    abstract:BACKGROUND:Fatal venous thromboembolism (VTE) is a rare complication of combined oral contraceptive (COC) treatment. This study aims to determine incidences of fatal VTE in relation to the type of COC and the percentage of cases reported to the Swedish Adverse Drug Reactions Advisory Committee (SADRAC). A further aim i...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.2165/00002018-200528100-00007

    authors: Hedenmalm K,Samuelsson E

    更新日期:2005-01-01 00:00:00

  • Traceability of Biologics in The Netherlands: An Analysis of Information-Recording Systems in Clinical Practice and Spontaneous ADR Reports.

    abstract:INTRODUCTION AND OBJECTIVE:Pharmacovigilance requirements for biologics mandate that EU Member States shall ensure that any biologic that is the subject of a suspected adverse drug reaction (ADR) is identifiable by brand name and batch number. Recent studies showed that brand name identification is well established, wh...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/s40264-015-0383-8

    authors: Klein K,Scholl JH,Vermeer NS,Broekmans AW,Van Puijenbroek EP,De Bruin ML,Stolk P

    更新日期:2016-02-01 00:00:00

  • Safety issues in the use of methylphenidate. An American perspective.

    abstract::Methylphenidate is the most widely use psychotropic medication in children in the US. It is both well tolerated and efficacious in the treatment of attention deficit hyperactivity disorder, and is associated with few serious adverse effects. However, the abuse of methylphenidate for the purpose of experiencing a 'high...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-199717030-00001

    authors: Rappley MD

    更新日期:1997-09-01 00:00:00

  • Antidepressants and the Risk of Hemorrhagic Stroke in the Elderly: a Nested Case-Control Study.

    abstract:BACKGROUND AND PURPOSE:Selective serotonin reuptake inhibitors (SSRIs) are frequently prescribed in the elderly due to a more favorable risk profile than other antidepressants (ADs). However, SSRIs are associated with an increased risk of gastrointestinal bleeding, while evidence on the risk of hemorrhagic stroke (HS) ...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/s40264-019-00837-y

    authors: Schäfer W,Princk C,Kollhorst B,Schink T

    更新日期:2019-09-01 00:00:00

  • Benefit-Risk Assessment of Blinatumomab in the Treatment of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia.

    abstract::Blinatumomab is the first-and-only Food and Drug Administration (FDA)-approved cluster of differentiation (CD) 19-directed CD3 bispecific T-cell engager (BiTE®) immunotherapy. It is currently FDA approved for the treatment of adults and children with Philadelphia chromosome-positive (Ph+) and Philadelphia chromosome-n...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.1007/s40264-018-0760-1

    authors: Stein A,Franklin JL,Chia VM,Arrindell D,Kormany W,Wright J,Parson M,Amouzadeh HR,Choudhry J,Joseph G

    更新日期:2019-05-01 00:00:00

  • Cardiovascular Profile of Valbenazine: Analysis of Pooled Data from Three Randomized, Double-Blind, Placebo-Controlled Trials.

    abstract:INTRODUCTION:Valbenazine is a novel vesicular monoamine transporter 2 inhibitor approved for the treatment of tardive dyskinesia in adults. OBJECTIVE:Using data from double-blind, placebo-controlled trials, analyses were conducted to evaluate the cardiovascular effects of once-daily valbenazine in patients with a psyc...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/s40264-017-0623-1

    authors: Thai-Cuarto D,O'Brien CF,Jimenez R,Liang GS,Burke J

    更新日期:2018-04-01 00:00:00

  • Oral contraceptives and venous thromboembolism: a systematic review and meta-analysis.

    abstract:BACKGROUND:An association between oral contraceptive (OC) use and venous thromboembolism (VTE) has long been recognized. However, no summary estimates of the increase in VTE risk associated with OC use have been available since 1995, and no meta-analyses have evaluated the VTE risk of new preparations containing drospi...

    journal_title:Drug safety

    pub_type: 杂志文章,meta分析,评审

    doi:10.2165/11598050-000000000-00000

    authors: Manzoli L,De Vito C,Marzuillo C,Boccia A,Villari P

    更新日期:2012-03-01 00:00:00

  • An algorithmic computerised order entry approach to assist in the prescribing of new therapeutic agents: case study of activated protein C at an academic medical centre.

    abstract:BACKGROUND:Academic medical centres face the need to care for patients with complex medical conditions, educate physicians-in-training and conduct research, all with increasingly constrained budgets. The adoption of new therapeutic technology presents challenges and opportunities in each of these areas. Severe sepsis r...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.2165/00002018-200427150-00008

    authors: Fischer MA,Lilly CM,Churchill WW,Baden LR,Avorn J

    更新日期:2004-01-01 00:00:00

  • Safety of Human Papillomavirus Vaccines: An Updated Review.

    abstract::Human papillomavirus (HPV) vaccines are now included in immunisation programmes in 71 countries. Unfortunately, uptake has been impacted in some countries by reduced confidence in the safety of the HPV vaccine. In 2013, we published an extensive review demonstrating a reassuring safety profile for bivalent (2vHPV) and...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.1007/s40264-017-0625-z

    authors: Phillips A,Patel C,Pillsbury A,Brotherton J,Macartney K

    更新日期:2018-04-01 00:00:00

  • Hepatic reactions during treatment of multiple sclerosis with interferon-beta-1a: incidence and clinical significance.

    abstract:BACKGROUND:Hepatic dysfunction, manifested as liver enzyme elevations, occurs frequently in patients who are treated with interferon, however, data for patients with multiple sclerosis are limited. OBJECTIVE:To retrospectively assess the safety profile of interferon-beta-1a therapy with respect to liver function durin...

    journal_title:Drug safety

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.2165/00002018-200326110-00006

    authors: Francis GS,Grumser Y,Alteri E,Micaleff A,O'Brien F,Alsop J,Stam Moraga M,Kaplowitz N

    更新日期:2003-01-01 00:00:00

  • Ethical and Practical Considerations in Removing Black Box Warnings from Drug Labels.

    abstract::Boxed warnings-also known as "black box" warnings-can be a powerful tool in communicating drug risks to physicians and patients. The overall number of boxed warnings has grown in recent years as the US Food and Drug Administration (FDA) has approved more drugs on the basis of limited pre-marketing information and as n...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/s40264-016-0419-8

    authors: Yeh JS,Sarpatwari A,Kesselheim AS

    更新日期:2016-08-01 00:00:00

  • The combined oral contraceptive. Risks and adverse effects in perspective.

    abstract::The risks and adverse effects of the low dose, new generation progestogen combined oral contraceptives (COCs) are much lower than original studies involving pills containing 50 micrograms estrogen. The main effects are those on the cardiovascular system, lipid and glucose metabolism and cancer. Any effect of the COC o...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-199512020-00002

    authors: Bagshaw S

    更新日期:1995-02-01 00:00:00

  • Reports of sexual disorders related to serotonin reuptake inhibitors in the French pharmacovigilance database: an example of underreporting.

    abstract:BACKGROUND:Depressive disorders and use of antidepressants are associated with adverse effects on sexual function. In pharmacoepidemiological studies, sexual disorders are reported by more than 50 % of patients taking serotonin reuptake inhibitors (SRIs). OBJECTIVE:The aim of this study was to determine the reporting ...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/s40264-013-0069-z

    authors: Trenque T,Maura G,Herlem E,Vallet C,Sole E,Auriche P,Drame M

    更新日期:2013-07-01 00:00:00

  • National ADR Monitoring System in China.

    abstract::It has been more than 25 years since an adverse drug reaction (ADR) monitoring agency was first established in China. In the past few years, the National ADR Monitoring System (NADRMS) has developed rapidly in the country. However, this system has not been reviewed in detail in the literature. Our aim was to demonstra...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.1007/s40264-016-0446-5

    authors: Hou Y,Li X,Wu G,Ye X

    更新日期:2016-11-01 00:00:00

  • Levodopa in Parkinson's disease: neurotoxicity issue laid to rest?

    abstract::Orally administered levodopa remains the most effective symptomatic treatment for Parkinson's disease. The introduction of levodopa therapy is often delayed, however, because of the fear that it might be toxic for the remaining dopaminergic neurons, and thus accelerate the deterioration of the patient's condition. Evi...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-199921050-00001

    authors: Murer MG,Raisman-Vozari R,Gershanik O

    更新日期:1999-11-01 00:00:00

  • Treatment with Selective Serotonin Reuptake Inhibitors in the Third Trimester of Pregnancy : Effects on the Infant.

    abstract::Pharmacotherapy in pregnant women is often necessary to treat chronic or relapsing depression or anxiety disorders. Studies that have evaluated the safety of selective serotonin reuptake inhibitors (SSRIs) in early pregnancy have not shown an enhanced risk of major congenital malformations and these results may have c...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-200528070-00002

    authors: Nordeng H,Spigset O

    更新日期:2005-07-01 00:00:00

  • Indicators of drug-seeking aberrant behaviours: the feasibility of use in observational post-marketing cohort studies for risk management.

    abstract:BACKGROUND:Problematic prescription drug use is reflected by or associated with drug-seeking aberrant behaviours. Research gaps include lack of post-marketing evidence and instruments. As part of the pharmacovigilance requirements, a risk management plan was developed for fentanyl buccal tablets (FEBT) by the manufactu...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/s40264-014-0193-4

    authors: Layton D,Osborne V,Al-Shukri M,Shakir SA

    更新日期:2014-08-01 00:00:00

  • Anticonvulsant-induced psychiatric disorders. The role of forced normalisation.

    abstract::With the introduction of several new anticonvulsant drugs into clinical practice in recent years, renewed attention has been paid to treatment-emergent effects, especially behavioural syndromes. In this review, the more severe psychiatric syndromes that may be associated with anticonvulsants are discussed, especially ...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-199615030-00001

    authors: Trimble MR

    更新日期:1996-09-01 00:00:00

  • Authors' Response to Braillon's Comment on: "Limited Evidence for Risk Factors for Proarrhythmia and Sudden Cardiac Death in Patients Using Antidepressants: Dutch Consensus on ECG Monitoring".

    abstract:: ...

    journal_title:Drug safety

    pub_type: 评论,信件

    doi:10.1007/s40264-018-0716-5

    authors: Simoons M,Seldenrijk A,Mulder H,van Roon E,Bakker R,Ruhé H

    更新日期:2018-12-01 00:00:00

  • Hydroxyurea in the treatment of HIV infection: clinical efficacy and safety concerns.

    abstract::Data from basic science and clinical studies suggest that hydroxyurea (hydroxycarbamide)-based regimens are effective treatment options for patients with HIV at various stages of disease. In vitro studies of HIV-infected lymphocytes have shown that hydroxyurea: (i) inhibits viral DNA synthesis; (ii) synergistically in...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-200326090-00002

    authors: Lisziewicz J,Foli A,Wainberg M,Lori F

    更新日期:2003-01-01 00:00:00

  • Discontinuation of beta-blockers and the risk of myocardial infarction in the elderly.

    abstract:BACKGROUND:It has been shown that the abrupt cessation of treatment with beta-adrenoceptor antagonists (beta-blockers) increases the risk of myocardial infarction in patients with hypertension. As beta-blockers differ in their pharmacokinetic and pharmacodynamic properties, this risk of discontinuation might also diffe...

    journal_title:Drug safety

    pub_type: 临床试验,杂志文章

    doi:10.2165/00002018-200730060-00008

    authors: Teichert M,de Smet PA,Hofman A,Witteman JC,Stricker BH

    更新日期:2007-01-01 00:00:00

  • Evaluation of Electronic Healthcare Databases for Post-Marketing Drug Safety Surveillance and Pharmacoepidemiology in China.

    abstract:INTRODUCTION:Electronic healthcare databases (EHDs) are used increasingly for post-marketing drug safety surveillance and pharmacoepidemiology in Europe and North America. However, few studies have examined the potential of these data sources in China. METHODS:Three major types of EHDs in China (i.e., a regional commu...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/s40264-017-0589-z

    authors: Yang Y,Zhou X,Gao S,Lin H,Xie Y,Feng Y,Huang K,Zhan S

    更新日期:2018-01-01 00:00:00

  • Effect of drug treatment on quality of life in mild to moderate heart failure.

    abstract::The most frequently reported symptoms in heart failure are fatigue and dyspnoea, which limit exercise tolerance. However, several surveys reveal other changes in physical and psychological well-being which affect the patient's perception of 'quality of life'. The introduction of new treatments for heart failure has st...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-199106040-00002

    authors: Waller DG

    更新日期:1991-07-01 00:00:00

  • Prospective data mining of six products in the US FDA Adverse Event Reporting System: disposition of events identified and impact on product safety profiles.

    abstract:BACKGROUND:The use of data mining has increased among regulators and pharmaceutical companies. The incremental value of data mining as an adjunct to traditional pharmacovigilance methods has yet to be demonstrated. Specifically, the utility in identifying new safety signals and the resources required to do so have not ...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.2165/11319000-000000000-00000

    authors: Bailey S,Singh A,Azadian R,Huber P,Blum M

    更新日期:2010-02-01 00:00:00

  • Improving safety reporting from randomised trials.

    abstract::Randomised clinical trials offer a unique opportunity for capturing safety information under a controlled setting that minimises biases in the comparison of different therapeutic options. Nevertheless, empirical evidence across diverse medical fields suggests that the reporting of safety information in clinical trials...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-200225020-00002

    authors: Ioannidis JP,Lau J

    更新日期:2002-01-01 00:00:00

  • Benefit-risk assessment of dronedarone in the treatment of atrial fibrillation.

    abstract::Rhythm control in atrial fibrillation (AF) can be achieved using pharmacological therapy. Amiodarone is the most efficacious anti-arrhythmic agent; however, its use is limited due to an unfavourable safety profile, including pro-arrhythmia, thyroid, liver, skin and pulmonary complications. Dronedarone, which is struct...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.1007/s40264-012-0012-8

    authors: Adlan AM,Lip GY

    更新日期:2013-02-01 00:00:00

  • PCSK9 Inhibitors and Neurocognitive Adverse Drug Reactions: Analysis of Individual Case Safety Reports from the Eudravigilance Database.

    abstract:INTRODUCTION:Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9Is) were associated with a risk of neurocognitive adverse drug reactions (ADRs). OBJECTIVE:We aimed to investigate the occurrence of neuropsychiatric ADRs related to PCSK9Is. METHODS:We analyzed Individual Case Safety Reports (ICSRs) sent thr...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/s40264-020-01021-3

    authors: di Mauro G,Zinzi A,Scavone C,Mascolo A,Gaio M,Sportiello L,Ferrajolo C,Rafaniello C,Rossi F,Capuano A

    更新日期:2020-12-22 00:00:00